Fenretinide (4-HPR): A preventive chance for women at genetic and familial risk?

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Cazzaniga, Massimiliano ^a   Varricchio, Clara ^a   Montefrancesco, Chiara ^a   Feroce, Irene ^a   Guerrieri Gonzaga, Aliana ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOOXYGENASE 2; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FENRETINIDE; HYDROGEN PEROXIDE; NITRIC OXIDE SYNTHASE; RETINOID; SOMATOMEDIN C; SUPEROXIDE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

APOPTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN MCF 7; DARK ADAPTATION; DRUG ACCUMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; METASTASIS; MUCOSAL DRYNESS; NIGHT BLINDNESS; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PROTEIN EXPRESSION; PRURITUS; RECEPTOR BINDING; REVIEW; TISSUE DIFFERENTIATION; TUMOR GROWTH; TUMOR PROMOTION; UNITED STATES; URTICARIA; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; OVARY TUMOR;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; FEMALE; FENRETINIDE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS;

EID: 84859731352     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/172897     Document Type: Review

References (63)

1. Chambon P., A decade of molecular biology of retinoic acid receptors FASEB Journal 1996 10 9 940 954 (Pubitemid 26285969)
2. Rehman F., Shanmugasundaram P., Schrey M. P., Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity British Journal of Cancer 2004 91 10 1821 1828 (Pubitemid 39664971)
3. Sun S. Y., Lotan R., Retinoids and their receptors in cancer development and chemoprevention Critical Reviews in Oncology/Hematology 2002 41 1 41 55 (Pubitemid 34051581)
4. Decensi A., Johansson H., Miceli R., Mariani L., Camerini T., Cavadini E., Di Mauro M. G., Barreca A., Gonzaga A. G., Diani S., Sandri M. T., De Palo G., Formelli F., Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer Cancer Epidemiology Biomarkers and Prevention 2001 10 10 1047 1053 (Pubitemid 32959151)
5. Gucev Z. S., Oh Y., Kelley K. M., Rosenfeld R. G., Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor 2-induced growth inhibition in human breast cancer cells Cancer Research 1996 56 7 1545 1550 (Pubitemid 26104017)
6. Nunes I., Kojima S., Rifkin D. B., Effects of endogenously activated transforming growth factor- on growth and differentiation of retinoic acid-treated HL-60 cells Cancer Research 1996 56 3 495 499 (Pubitemid 26043645)
7. Pfahl M., Nuclear receptor/AP-1 interaction Endocrine Reviews 1993 14 5 651 658 (Pubitemid 23320391)
8. Dedieu S., Lefebvre P., Retinoids interfere with the AP1 signalling pathway in human breast cancer cells Cellular Signalling 2006 18 6 889 898 (Pubitemid 43208942)
9. Moon R. C., McCormick D. L., Mehta R. G., Inhibition of carcinogenesis by retinoids Cancer Research 1983 43 5 2469 2475 (Pubitemid 13126759)
10. Anzano M. A., Byers S. W., Smith J. M., Peer C. W., Mullen L. T., Brown C. C., Roberts A. B., Sporn M. B., Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen Cancer Research 1994 54 17 4614 4617 (Pubitemid 24276483)
11. Anzano M. A., Peer C. W., Smith J. M., Mullen L. T., Shrader M. W., Logsdon D. L., Driver C. L., Brown C. C., Roberts A. B., Sporn M. B., Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid Journal of the National Cancer Institute 1996 88 2 123 125 (Pubitemid 26020101)
12. Wu K., Kim H. T., Rodriquez J. L., Hilsenbeck S. G., Mohsin S. K., Xu X. C., Lamph W. W., Kuhn J. G., Green J. E., Brown P. H., Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069 Cancer Epidemiology Biomarkers and Prevention 2002 11 5 467 474 (Pubitemid 34517942)
13. Wu K., Kim H. T., Rodriquez J. L., Munoz-Medellin D., Mohsin S. K., Hilsenbeck S. G., Lamph W. W., Gottardis M. M., Shirley M. A., Kuhn J. G., Green J. E., Brown P. H., 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice Clinical Cancer Research 2000 6 9 3696 3704
14. Wu K., Zhang Y., Xu X. C., Hill J., Celestino J., Kim H. T., Mohsin S. K., Hilsenbeck S. G., Lamph W. W., Bissonette R., Brown P. H., The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice Cancer Research 2002 62 22 6376 6380 (Pubitemid 35364089)
15. Gottardis M. M., Bischoff E. D., Shirley M. A., Wagoner M. A., Lamph W. W., Heyman R. A., Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR- selective ligand Cancer Research 1996 56 24 5566 5570 (Pubitemid 26422151)
16. Sun S. Y., Li W., Yue P., Lippman S. M., Hong W. K., Lotan R., Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms Cancer Research 1999 59 10 2493 2498 (Pubitemid 29242302)
17. Sheikh M. S., Shao Z. M., Li X. S., Ordonez J. V., Conley B. A., Dawson M. I., Han Q. X., Chao W., Quick T., Niles R. M., Fontana J. A., N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma Carcinogenesis 1995 16 10 2477 2486
18. Fanjul A. N., Delia D., Pierotti M. A., Rideout D., Qiu J. Q., Pfahl M., 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors Journal of Biological Chemistry 1996 271 37 22441 22446 (Pubitemid 26304679)
19. Giandomenico V., Andreola F., Rodriguez de la Concepcion M. L., Collins S. J., de Luca L. M., Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells) Carcinogenesis 1999 20 6 1133 1135 (Pubitemid 29263763)
20. Anding A. L., Chapman J. S., Barnett D. W., Curley R. W. Jr., Clagett-Dame M., The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase-dependent and independent of the retinoic acid receptor Cancer Research 2007 67 13 6270 6277 (Pubitemid 47037509)
21. D'Elia D., Aiello A., Lombardi L., Pelicci P. G., Grignani F., Grignani F., Formelli F., Menard S., Costa A., Veronesi U., Pierotti M. A., N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid Cancer Research 1993 53 24 6036 6041
22. Lotan R., Retinoids and apoptosis: implications for cancer chemoprevention and therapy Journal of the National Cancer Institute 1995 87 22 1655 1657
23. Holmes W. F., Soprano D. R., Soprano K. J., Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR Journal of Cellular Biochemistry 2003 89 2 262 278 (Pubitemid 36547261)
24. Holmes W. F., Soprano D. R., Soprano K. J., Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines Journal of Cellular Physiology 2004 199 3 317 329 (Pubitemid 38580429)
25. Appierto V., Tiberio P., Cavadini E., Casalini P., Cappelletti G., Formelli F., Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity Molecular Cancer Therapeutics 2009 8 12 3360 3368
26. Oridate N., Suzuki S., Higuchi M., Mitchell M. F., Hong W. K., Lotan R., Involvement of reactive oxygen species in N-(4- hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells Journal of the National Cancer Institute 1997 89 16 1191 1198 (Pubitemid 27350028)
27. Delia D., Aiello A., Meroni L., Nicolini M., Reed J. C., Pierotti M. A., Role of antioxidants and intracellular free radicals in retinamide-induced cell death Carcinogenesis 1997 18 5 943 948 (Pubitemid 28132338)
28. Tosetti F., Ven R., Arena G., Morini M., Minghelli S., Noonan D. M., Albini A., N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death Molecular Pharmacology 2003 63 3 565 573 (Pubitemid 36297326)
29. Maurer B. J., Melton L., Billups C., Cabot M. C., Reynolds C. P., Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism Journal of the National Cancer Institute 2000 92 23 1897 1909 (Pubitemid 32036920)
30. Sporn M. B., Dunlop N. M., Newton D. L., Smith J. M., Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Federation Proceedings 1976 35 6 1332 1338
31. Moon R. C., Thompson H. J., Becci P. J., N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat Cancer Research 1979 39 4 1339 1346 (Pubitemid 9183854)
32. Kelloff G. J., Crowell J. A., Boone C. W., Steele V. E., Lubet R. A., Greenwald P., Alberts D. S., Covey J. M., Doody L. A., Knapp G. G., Clinical development plan: N-(4-hydroxyphenyl)retinamide Journal of cellular biochemistry. Supplement 1994 20 176 196
33. Mehta R. G., Moon R. C., Hawthorne M., Formelli F., Costa A., Distribution of fenretinide in the mammary gland of breast cancer patients European Journal of Cancer 1991 27 2 138 141
34. Chapman J. S., Weiss K. L., Curley R. W. Jr., Highland M. A., Clagett-Dame M., Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis Archives of Biochemistry and Biophysics 2003 419 2 234 243 (Pubitemid 37329990)
35. Reynolds C. P., Matthay K. K., Villablanca J. G., Maurer B. J., Retinoid therapy of high-risk neuroblastoma Cancer Letters 2003 197 1-2 185 192 (Pubitemid 36860009)
36. O'Donnell P. H., Guo W. X., Reynolds C. P., Maurer B. J., N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes Leukemia 2002 16 5 902 910 (Pubitemid 34537564)
37. Batra S., Reynolds C. P., Maurer B. J., Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators Cancer Research 2004 64 15 5415 5424 (Pubitemid 39006564)
38. Costa A., Malone W., Perloff M., Buranelli F., Campa T., Dossena G., Magni A., Pizzichetta M., Andreoli C., Del Vecchio M., Formelli F., Barbieri A., Tolerability of the synthetic retinoid fenretinide (HPR) European Journal of Cancer and Clinical Oncology 1989 25 5 805 808 (Pubitemid 19164323)
39. Formelli F., Carsana R., Costa A., Buranelli F., Campa T., Dossena G., Magni A., Pizzichetta M., Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients Cancer Research 1989 49 21 6149 6152 (Pubitemid 19274183)
40. Veronesi U., de Palo G., Marubini E., Costa A., Formelli F., Mariani L., Decensi A., Camerini T., Del Turco M. R., Di Mauro M. G., Muraca M. G., Del Vecchio M., Pinto C., D'Aiuto G., Boni C., Campa T., Magni A., Miceli R., Perloff M., Malone W. F., Sporn M. B., Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer Journal of the National Cancer Institute 1999 91 21 1847 1856
41. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R., Di Mauro M. G., Costa A., Marubini E., Sporn M. B., De Palo G., Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Annals of Oncology 2006 17 7 1065 1071 (Pubitemid 43985241)
42. Simeone A. M., Deng C. X., Kelloff G. J., Steele V. E., Johnson M. M., Tari A. M., N-(4-hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells Carcinogenesis 2005 26 5 1000 1007 (Pubitemid 41214330)
43. Baserga R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research 1995 55 2 249 252
44. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 1998 351 9113 1393 1396 (Pubitemid 28209997)
45. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M., Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study Science 1998 279 5350 563 566 (Pubitemid 28067285)
46. Yu H., Spitz M. R., Mistry J., Gu J., Hong W. K., Wu X., Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis Journal of the National Cancer Institute 1999 91 2 151 156 (Pubitemid 29042692)
47. Ma J., Pollak M. N., Giovannucci E., Chan J. M., Tao Y., Hennekens C. H., Stampfer M. J., Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 Journal of the National Cancer Institute 1999 91 7 620 625 (Pubitemid 29194048)
48. Favoni R. E., de Cupis A., Bruno S., Yee D., Ferrera A., Pirani P., Costa A., Decensi A., Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines British Journal of Cancer 1998 77 12 2138 2147 (Pubitemid 28263933)
49. Torrisi R., Pensa F., Orengo M. A., Catsafados E., Ponzani P., Boccardo F., Costa A., Decensi A., The synthetic retinoid fenretinide lowers plasma insulin-like growth factor-I levels in breast cancer patients Cancer Research 1993 53 20 4769 4771 (Pubitemid 23326163)
50. Simeone A. M., Li Y. J., Broemeling L. D., Johnson M. M., Tuna M., Tari A. M., Cyclooxygenase-2 Is Essential for HER2/neu to Suppress N-(4-Hydroxyphenyl)retinamide apoptotic effects in breast cancer cells Cancer Research 2004 64 4 1224 1228 (Pubitemid 38235585)
51. Camerini T., Mariani L., de Palo G., Marubini E., Di Mauro M. G., Decensi A., Costa A., Veronesi U., Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer Journal of Clinical Oncology 2001 19 6 1664 1670 (Pubitemid 32230866)
52. Decensi A., Torrisi R., Gozza A., Severi G., Bertelli G., Fontana V., Pensa F., Carozzo L., Traverseo A., Milone S., Dini D., Costa A., Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer Breast Cancer Research and Treatment 1999 53 2 145 151 (Pubitemid 29161120)
53. Zujewski J., Pai L., Wakefield L., Giusti R., Dorr F. A., Flanders C., Caruso R., Kaiser M., Goodman L., Merino M., Gossard M., Noone M. A., Denicoff A., Venzon D., Cowan K. H., O'Shaughnessy J. A., Tamoxifen and fenretinide in women with metastatic breast cancer Breast Cancer Research and Treatment 1999 57 3 277 283
54. Cobleigh M. A., Dowlatshahi K., Deutsch T. A., Mehta R. G., Moon R. C., Minn F., Benson A. B., Rademaker A. W., Ashenhurst J. B., Wade J. L., Wolter J., Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer Journal of Clinical Oncology 1993 11 3 474 477 (Pubitemid 23071044)
55. Doose D. R., Minn F. L., Stellar S., Nayak R. K., Effects of meals and meal composition on the bioavailability of fenretinide Journal of Clinical Pharmacology 1992 32 12 1089 1095 (Pubitemid 23033660)
56. Formelli F., Clerici M., Campa T., Di Mauro M. G., Magni A., Mascotti G., Moglia D., De Palo G., Costa A., Veronesi U., Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations Journal of Clinical Oncology 1993 11 10 2036 2042 (Pubitemid 23304631)
57. Peng Y. M., Dalton W. S., Alberts D. S., Xu M. J., Lim H., Meyskens F. L., Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients International Journal of Cancer 1989 43 1 22 26 (Pubitemid 19039109)
58. Ratko T. A., Detrisac C. J., Dinger N. M., Thomas C. F., Kelloff G. J., Moon R. C., Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats Cancer Research 1989 49 16 4472 4476 (Pubitemid 19208347)
59. Conley B., O'Shaughnessy J., Prindiville S., Lawrence J., Chow C., Jones E., Merino M. J., Kaiser-Kupfer M. I., Caruso R. C., Podgor M., Goldspiel B., Venzon D., Danforth D., Wu S., Noone M., Goldstein J., Cowan K. H., Zujewski J., Pilot trial of the safety, tolerability, and retinoid levels of N-(4- hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer Journal of Clinical Oncology 2000 18 2 275 283 (Pubitemid 30056415)
60. Decensi A., Robertson C., Guerrieri-Gonzaga A., Serrano D., Cazzaniga M., Mora S., Gulisano M., Johansson H., Galimberti V., Cassano E., Moroni S. M., Formelli F., Lien E. A., Pelosi G., Johnson K. A., Bonanni B., Randomized double-blind 2 X 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women Journal of Clinical Oncology 2009 27 23 3749 3756
61. Decensi A., Bonanni B., Baglietto L., Guerrieri-Gonzaga A., Ramazzotto F., Johansson H., Robertson C., Marinucci I., Mariette F., Sandri M. T., Daldoss C., Bianco V., Buttarelli M., Cazzaniga M., Franchi D., Cassano E., Omodei U., A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers Clinical Cancer Research 2004 10 13 4389 4397 (Pubitemid 38878879)
62. de Palo G., Veronesi U., Camerini T., Formelli F., Mascotti G., Boni C., Fosser V., Del Vecchio M., Campa T., Costa A., Marubini E., Can fenretinide protect women against ovarian cancer? Journal of the National Cancer Institute 1995 87 2 146 147
63. de Palo G., Mariani L., Camerini T., Marubini E., Formelli F., Pasini B., Decensi A., Veronesi U., Effect of fenretinide on ovarian carcinoma occurrence Gynecologic Oncology 2002 86 1 24 27 (Pubitemid 34757046)